Generic drug (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Generic drug" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
7th place
7th place
11th place
8th place
332nd place
246th place
22nd place
19th place
low place
low place
621st place
380th place
low place
low place
5th place
5th place
896th place
674th place
low place
low place
5,344th place
3,420th place
102nd place
76th place
low place
low place
low place
low place
49th place
47th place
987th place
560th place
low place
low place
14th place
14th place
low place
low place
low place
low place
390th place
227th place
low place
8,167th place
low place
low place
low place
low place
low place
low place
low place
low place
910th place
593rd place
low place
low place
low place
low place
7,147th place
3,830th place
3,811th place
2,160th place
6,282nd place
3,410th place
low place
8,037th place
low place
low place
low place
low place
928th place
651st place
low place
8,921st place
low place
low place
apotex.com (Global: low place; English: low place)
- "Apotex press release on successful challenge of Norvasc patent". Archived from the original on 2018-03-19. Retrieved 2017-12-18.
- "Apotex press release on successful challenge of Paxil patent". Archived from the original on August 7, 2007.
archive-it.org (Global: 910th place; English: 593rd place)
wayback.archive-it.org
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians" (PDF). The Canadian Journal of Clinical Pharmacology. 12 (3): e229–e239. PMID 16278495. Archived from the original (PDF) on 2007-11-29.
archive.today (Global: 14th place; English: 14th place)
- Joynson C (4 April 2012). "Price decay after loss of brand exclusivity (patent expiry) and generic launch". PharmaPhorum. Archived from the original on 31 January 2013.
asm.org (Global: 3,555th place; English: low place)
journals.asm.org
- Weinstein, Zohar B.; Zaman, Muhammad H. (21 December 2018). "Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01243-18. ISSN 0066-4804. PMC 6325213. PMID 30397062.
bms.com (Global: low place; English: low place)
newsroom.bms.com
- "Bristol-Myers Squibb press release on successful defense of Plavix patent". Archived from the original on 2007-07-04.
news.bms.com
- "Bristol-Myers Squibb - Newsroom - News Releases". Archived from the original on 2007-10-16. Retrieved 2018-12-20.
cardozolawreview.com (Global: low place; English: low place)
- Carrier MA, Wander D (2012). "Citizen Petitions: An Empirical Study" (PDF). Cardozo Law Review. 34: 249–293. Archived from the original (PDF) on 2016-08-03. Retrieved 2016-09-14.
cato.org (Global: 4,789th place; English: 3,253rd place)
- "Disciplining China's Trade Practices at the WTO: How WTO Complaints Can Help Make China More Market-Oriented". Cato Institute. 2018-11-15. Retrieved 2020-04-08.
cdc.gov (Global: 218th place; English: 212th place)
- Nickerson, Jason W.; Attaran, Amir; Westerberg, Brian D.; Curtis, Sharon; Overton, Sean; Mayer, Paul (1 January 2016). "Fatal Bacterial Meningitis Possibly Associated with Substandard Ceftriaxone - Uganda, 2013". Morbidity and Mortality Weekly Report. 64 (50): 1375–1377.
cjcp.ca (Global: low place; English: low place)
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians" (PDF). The Canadian Journal of Clinical Pharmacology. 12 (3): e229–e239. PMID 16278495. Archived from the original (PDF) on 2007-11-29.
clihouston.com (Global: low place; English: low place)
- "The role of reverse engineering in the development of generic formulations". www.clihouston.com. Archived from the original on 18 October 2020. Retrieved 23 May 2017.
cnn.com (Global: 28th place; English: 26th place)
- Mears B (2011-06-23). "High Court sides with generic drug makers in narrow ruling". CNN. Retrieved 2013-01-01.
consumerlab.com (Global: low place; English: low place)
- "Drug Tests: Wellbutrin vs. Generic Bupropion". 2012-12-06. Retrieved 2013-04-20.
cornell.edu (Global: 332nd place; English: 246th place)
law.cornell.edu
doi.org (Global: 2nd place; English: 2nd place)
- Gupta H, Kumar S, Roy SK, Gaud RS (January 2010). "Patent protection strategies". Journal of Pharmacy & Bioallied Sciences. 2 (1): 2–7. doi:10.4103/0975-7406.62694. PMC 3146086. PMID 21814422.
- DiMasi JA, Hansen RW, Grabowski HG (March 2003). "The price of innovation: new estimates of drug development costs". Journal of Health Economics. 22 (2): 151–185. doi:10.1016/s0167-6296(02)00126-1. hdl:10161/6706. PMID 12606142.
- Sabatini MT, Silva M (August 2020). "Patent Cliffs in the Era of Complex Therapies and Biologics". Pharmaceutical Medicine. 34 (4): 271–278. doi:10.1007/s40290-020-00348-7. PMID 32772314. S2CID 221071039.
- Boehm G, Yao L, Han L, Zheng Q (September 2013). "Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984". Acta Pharmaceutica Sinica B. 3 (5): 297–311. doi:10.1016/j.apsb.2013.07.004.
- Page A, Etherton-Beer C (January 2018). "Choosing a medication brand: Excipients, food intolerance and prescribing in older people". Maturitas. 107: 103–109. doi:10.1016/j.maturitas.2017.11.001. PMID 29169573.
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH (2009). "Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration". Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.
- Warren JB (January 2013). "Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?". British Journal of Clinical Pharmacology. 75 (1): 7–14. doi:10.1111/j.1365-2125.2012.04323.x. PMC 3555041. PMID 22574725.
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. (October 2009). "Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration". The Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.
- Calo-Fernández B, Martínez-Hurtado JL (December 2012). "Biosimilars: company strategies to capture value from the biologics market". Pharmaceuticals. 5 (12): 1393–1408. doi:10.3390/ph5121393. PMC 3816668. PMID 24281342.
- Elhauge E, Krueger A (2012-12-21). "Solving the Patent Settlement Puzzle". Texas Law Review. doi:10.2139/ssrn.2125456. S2CID 154797144. SSRN 2125456.
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials". The Annals of Pharmacotherapy. 39 (7–8): 1188–1193. doi:10.1345/aph.1G003. PMID 15914517. S2CID 11685122. Archived from the original on 2011-06-16.
- Haley GT, Haley UC (2012). "The effects of patent-law changes on innovation: The case of India's pharmaceutical industry". Technological Forecasting and Social Change. 79 (4): 607–619. doi:10.1016/j.techfore.2011.05.012.
- Caudron, J.‐M.; Ford, N.; Henkens, M.; Macé, C.; Kiddle‐Monroe, R.; Pinel, J. (August 2008). "Substandard medicines in resource‐poor settings: a problem that can no longer be ignored". Tropical Medicine & International Health. 13 (8): 1062–1072. doi:10.1111/j.1365-3156.2008.02106.x. ISSN 1360-2276.
- Weinstein, Zohar B.; Zaman, Muhammad H. (21 December 2018). "Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01243-18. ISSN 0066-4804. PMC 6325213. PMID 30397062.
europa.eu (Global: 68th place; English: 117th place)
ec.europa.eu
- "The Rules Governing Medicinal Products in the European Union". EudraLex. Archived from the original on 2010-05-28. Retrieved 15 June 2008.
emea.europa.eu
- "European Medicines Agency". Archived from the original on 2009-12-22. Retrieved 15 June 2008.
fda.gov (Global: 447th place; English: 338th place)
- Generic Drug Facts, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 2017-10-06, retrieved 2017-11-11
- "Food & Drug Administration, Generic Drugs: Questions and Answers". Food and Drug Administration. January 12, 2010. Archived from the original on June 9, 2009. Retrieved 2010-02-03.
- "Biosimilar and Interchangeable Products". U.S. Food and Drug Administration. Archived from the original on November 1, 2017. Retrieved 5 May 2018.
- "Pediatric Research Equity Act of 2007" (PDF). Food and Drug Administration. Archived from the original (PDF) on July 9, 2009.
- "FAQ on generic drugs". FDA. Food and drug administration. Retrieved 21 May 2018.
- "FDA White Paper: Generic Drug Prices in the US Are Lower Than Drug Prices in Canada". FDA. 6.US Food and Drug Administration, Office of Planning. Archived from the original on February 20, 2004. Retrieved 21 May 2018.
- "Savings From Generic Drugs Purchased at Retail Pharmacies". Food and Drug Administration. April 2004. Archived from the original on 2008-02-23. Retrieved 2008-07-11.
- "Generic Initiative for Value and Efficiency (GIVE)". FDA. October 4, 2007. Archived from the original on October 18, 2007. Retrieved 2008-06-15.
- "Orange Book Annual Preface, Statistical Criteria for Bioequivalence". Approved Drug Products with Therapeutic Equivalence Evaluations 29th Edition. U.S. Food and Drug Administration Center for Drug Evaluation and Research. 2009-06-18. Archived from the original on June 6, 2009. Retrieved 2009-08-10.
- "Facts about Generic Drugs". Food and Drug Administration. 26 April 2019.
- "Approved Drug Products with Therapeutic Equivalence Evaluations, Preface". U.S. Food and Drug Administration. Archived from the original on August 19, 2000. – an explanation of FDA terms and procedures
- "Guidance for Industry: 180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act" (PDF). FDA, Center for Drug Evaluation and Research (CDER). June 1998. Archived from the original (PDF) on July 10, 2009. Retrieved August 24, 2009.
- "Paragraph IV Drug Product Applications: Generic Drug Patent Challenge Notifications". FDA, Office of Generic Drugs (OGD). 2008-06-11. Archived from the original on January 23, 2001. Retrieved 2008-06-16.
- "FDA Update: Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg". U.S. Food and Drug Administration. 2012-10-03. Archived from the original on October 6, 2012. Retrieved 2013-04-20.
fiercepharma.com (Global: low place; English: 8,921st place)
- Lane EJ (16 March 2016). "China FDA lays down new guidelines on bioequivalence for generics". FiercePharma.
ftc.gov (Global: 3,796th place; English: 2,268th place)
- "#223: Authorized Generic Drug Study". U.S. Federal Trade Administration (FTC). August 2011. Archived from the original on 2017-05-16. Retrieved 2016-09-14.
- "Authorized Generic Drugs: Short-Term Effects and Long-Term ImpactAuthorized Generic Drugs: Short-Term Effects and Long-Term Impact" (PDF). U.S. Federal Trade Administration (FTC). August 2011.
gphaonline.org (Global: low place; English: low place)
- "Generic Drug Savings in the U.S" (PDF). Washington, DC: Generic Pharmaceutical Association (GPhA). 2015. Retrieved 16 June 2016.
- "Authorized Generics". Generic Pharmaceutical Association (GPhA). 2008. Archived from the original on 2008-05-29. Retrieved 2008-06-16.
gpo.gov (Global: 1,360th place; English: 845th place)
access.gpo.gov
- "Part 320--Bioavailability and Bioequivalence Requirements". U.S. Food and Drug Administration, Department of Health and Human Services. 1 April 2008. Code of Federal Regulations 320 Title 21, Volume 5 CFR 320 21/5. Archived from the original on 2008-10-08. Retrieved 15 June 2008.
handle.net (Global: 102nd place; English: 76th place)
hdl.handle.net
- DiMasi JA, Hansen RW, Grabowski HG (March 2003). "The price of innovation: new estimates of drug development costs". Journal of Health Economics. 22 (2): 151–185. doi:10.1016/s0167-6296(02)00126-1. hdl:10161/6706. PMID 12606142.
hc-sc.gc.ca (Global: low place; English: 8,167th place)
- "Drugs and Health Products, Bioavailability and Bioequivalence". Health Canada, Guidance Documents. Health Canada. 8 June 2005. Retrieved 15 June 2008.
hsj.co.uk (Global: low place; English: 6,091st place)
- "No-deal Brexit 'will force up price of generic drugs'". Health Service Journal. 26 September 2018. Retrieved 4 November 2018.
iitb.ac.in (Global: low place; English: 8,037th place)
ircc.iitb.ac.in
- "The Patent Act, 1970". www.ircc.iitb.ac.in. Archived from the original on April 30, 2010.
latimes.com (Global: 22nd place; English: 19th place)
- Lazarus, David (March 25, 2013). "An insider's view of generic-drug pricing". Los Angeles Times. Archived from the original on August 4, 2019. Retrieved December 26, 2025.
- Healy M (2012-10-05). "Generic antidepressant pulled from U.S. shelves after FDA finding". Los Angeles Times. Retrieved 2013-04-20.
law360.com (Global: 6,282nd place; English: 3,410th place)
- Casey S (24 October 2012). "Generic Pharmaceutical Liability: Challenges And Changes". Law360.
livemint.com (Global: 390th place; English: 227th place)
- Altstedter A (18 May 2017). "Glenmark's Glenn Saldanha seeks a new holy grail as generic drugs run dry". Live Mint.
marketrealist.com (Global: low place; English: low place)
- Benson M (February 20, 2015). "What it takes to be called 'big pharma' – Market Realist". Market Realist.
marketresearchcommunity.com (Global: low place; English: low place)
- "Global Generic Drugs Market by Type (Simple Generic Drugs, super Generic drugs, Biosimilar), Application (Anti-infective, Cardiovascular, Central Nervous System, Diabetes, Oncology, Respiratory, Rheumatology), and Region (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Russia, Spain, Italy, Benelux, Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific), Latin America (Brazil, Argentina, Chile, and Rest of Latin America), and Middle East and Africa (GCC, Turkey, and South America) Growth, Trends, Covid-19 Impact, And Forecasts (2022-2028)". Market Research Community. Reports Insights Consulting Pvt Ltd. 29 April 2022. Retrieved 5 May 2022.
nih.gov (Global: 4th place; English: 4th place)
pubmed.ncbi.nlm.nih.gov
- Gupta H, Kumar S, Roy SK, Gaud RS (January 2010). "Patent protection strategies". Journal of Pharmacy & Bioallied Sciences. 2 (1): 2–7. doi:10.4103/0975-7406.62694. PMC 3146086. PMID 21814422.
- DiMasi JA, Hansen RW, Grabowski HG (March 2003). "The price of innovation: new estimates of drug development costs". Journal of Health Economics. 22 (2): 151–185. doi:10.1016/s0167-6296(02)00126-1. hdl:10161/6706. PMID 12606142.
- Sabatini MT, Silva M (August 2020). "Patent Cliffs in the Era of Complex Therapies and Biologics". Pharmaceutical Medicine. 34 (4): 271–278. doi:10.1007/s40290-020-00348-7. PMID 32772314. S2CID 221071039.
- Page A, Etherton-Beer C (January 2018). "Choosing a medication brand: Excipients, food intolerance and prescribing in older people". Maturitas. 107: 103–109. doi:10.1016/j.maturitas.2017.11.001. PMID 29169573.
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH (2009). "Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration". Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.
- Warren JB (January 2013). "Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?". British Journal of Clinical Pharmacology. 75 (1): 7–14. doi:10.1111/j.1365-2125.2012.04323.x. PMC 3555041. PMID 22574725.
- Mossinghoff GJ (1999). "Overview of the Hatch-Waxman Act and its impact on the drug development process" (PDF). Food and Drug Law Journal. 54 (2): 187–194. PMID 11758572.
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. (October 2009). "Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration". The Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.
- Calo-Fernández B, Martínez-Hurtado JL (December 2012). "Biosimilars: company strategies to capture value from the biologics market". Pharmaceuticals. 5 (12): 1393–1408. doi:10.3390/ph5121393. PMC 3816668. PMID 24281342.
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials". The Annals of Pharmacotherapy. 39 (7–8): 1188–1193. doi:10.1345/aph.1G003. PMID 15914517. S2CID 11685122. Archived from the original on 2011-06-16.
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians" (PDF). The Canadian Journal of Clinical Pharmacology. 12 (3): e229–e239. PMID 16278495. Archived from the original (PDF) on 2007-11-29.
- Weinstein, Zohar B.; Zaman, Muhammad H. (21 December 2018). "Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01243-18. ISSN 0066-4804. PMC 6325213. PMID 30397062.
ncbi.nlm.nih.gov
- Gupta H, Kumar S, Roy SK, Gaud RS (January 2010). "Patent protection strategies". Journal of Pharmacy & Bioallied Sciences. 2 (1): 2–7. doi:10.4103/0975-7406.62694. PMC 3146086. PMID 21814422.
- Warren JB (January 2013). "Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?". British Journal of Clinical Pharmacology. 75 (1): 7–14. doi:10.1111/j.1365-2125.2012.04323.x. PMC 3555041. PMID 22574725.
- Calo-Fernández B, Martínez-Hurtado JL (December 2012). "Biosimilars: company strategies to capture value from the biologics market". Pharmaceuticals. 5 (12): 1393–1408. doi:10.3390/ph5121393. PMC 3816668. PMID 24281342.
- Weinstein, Zohar B.; Zaman, Muhammad H. (21 December 2018). "Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01243-18. ISSN 0066-4804. PMC 6325213. PMID 30397062.
nihs.go.jp (Global: low place; English: low place)
- "National Institute for Health Sciences, Division of Drugs Guidances". Japan. Archived from the original on 2019-05-15. Retrieved 15 June 2008.
nmc.org.in (Global: low place; English: low place)
- "Code of Medical Ethics Regulations, 2002 | NMC". National Medical Commission.
Every physician should, as far as possible, prescribe drugs with generic names and he / she shall ensure that there is a rational prescription and use of drugs.
nps.org.au (Global: low place; English: low place)
- "Generic medicines training kit: safe and appropriate use of generic medicines". Pharmaceutical Society of Australia Competency Standards for Pharmacists in Australia 2003. National Prescribing Service Limited (NPS). 2003-07-09. Archived from the original on 2009-10-20. Retrieved 2010-01-24."Prescribers may disallow brand switching by ticking the relevant box on the PBS prescription form"
nytimes.com (Global: 7th place; English: 7th place)
- Frakt A (28 September 2015). "How Patent Law Can Block Even Lifesaving Drugs". The New York Times.
- Wyatt E (17 June 2013). "Supreme Court Lets Regulators Sue Over Generic Drug Deals". New York Times. Retrieved 9 May 2015.
- Strickland C (15 October 1989). "Bolar: A Drug Company Under Siege". The New York Times.
- Freudenheim M (10 September 1989). "Exposing the F.D.A." The New York Times.
- Andrews EL (31 July 1989). "F.D.A. Inquiry on Generic Drugs Focuses on Changes in Ingredients". The New York Times.
- Eban K (11 May 2019). "Americans Need Generic Drugs. But Can They Trust Them?". The New York Times. Retrieved 2019-05-15.
- Liptak A (23 June 2011). "Drug Makers Win Two Supreme Court Decisions". New York Times.
pharmacytimes.com (Global: low place; English: low place)
- "Branded Generics: Misunderstood, but Lucrative". Pharmacy Times. 1 October 2008. Retrieved 21 May 2018.
pharmaphorum.com (Global: low place; English: low place)
- Joynson C (4 April 2012). "Price decay after loss of brand exclusivity (patent expiry) and generic launch". PharmaPhorum. Archived from the original on 31 January 2013.
plg-group.com (Global: low place; English: low place)
- Mossinghoff GJ (1999). "Overview of the Hatch-Waxman Act and its impact on the drug development process" (PDF). Food and Drug Law Journal. 54 (2): 187–194. PMID 11758572.
reuters.com (Global: 49th place; English: 47th place)
- Dasgupta N, Miglani S (12 July 2018). "Exclusive: With U.S. trade under a cloud, China opens to Indian pharma". Reuters. Retrieved 12 April 2020.
scientificamerican.com (Global: 896th place; English: 674th place)
- Mogalian, Erik; Myrdal, Paul; DeShong, Philip (13 December 2004). "What's the difference between brand-name and generic prescription drugs?". Scientific American. Retrieved 2017-11-11.
scotusblog.com (Global: 7,147th place; English: 3,830th place)
- "PLIVA, Inc. v. Mensing". SCOTUS Blog. Retrieved 23 May 2017.
scroll.in (Global: 676th place; English: 420th place)
- Reddy P (April 12, 2017). "India makes a long overdue move to ensure better drug safety". Scroll.in.
seekingalpha.com (Global: 5,344th place; English: 3,420th place)
- "Big Pharma Embraces Branded Generics". Seeking Alpha. 2010-10-31. Retrieved 21 May 2018.
semanticscholar.org (Global: 11th place; English: 8th place)
api.semanticscholar.org
- Sabatini MT, Silva M (August 2020). "Patent Cliffs in the Era of Complex Therapies and Biologics". Pharmaceutical Medicine. 34 (4): 271–278. doi:10.1007/s40290-020-00348-7. PMID 32772314. S2CID 221071039.
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH (2009). "Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration". Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. (October 2009). "Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration". The Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.
- Elhauge E, Krueger A (2012-12-21). "Solving the Patent Settlement Puzzle". Texas Law Review. doi:10.2139/ssrn.2125456. S2CID 154797144. SSRN 2125456.
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials". The Annals of Pharmacotherapy. 39 (7–8): 1188–1193. doi:10.1345/aph.1G003. PMID 15914517. S2CID 11685122. Archived from the original on 2011-06-16.
ssrn.com (Global: 703rd place; English: 501st place)
papers.ssrn.com
- Elhauge E, Krueger A (2012-12-21). "Solving the Patent Settlement Puzzle". Texas Law Review. doi:10.2139/ssrn.2125456. S2CID 154797144. SSRN 2125456.
supremecourt.gov (Global: 3,811th place; English: 2,160th place)
- "564 PLIVA, Inc. v. Mensing" (PDF). Supreme Court of the United States. 2011. Archived from the original (PDF) on 2013-05-12.
theannals.com (Global: low place; English: low place)
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials". The Annals of Pharmacotherapy. 39 (7–8): 1188–1193. doi:10.1345/aph.1G003. PMID 15914517. S2CID 11685122. Archived from the original on 2011-06-16.
theconversation.com (Global: 928th place; English: 651st place)
- "The world needs pharmaceuticals from China and India to beat coronavirus". 2020-05-25. Retrieved 2020-10-13.
theprint.in (Global: 987th place; English: 560th place)
torreya.com (Global: low place; English: low place)
- "Top Global Pharmaceutical Company Report" (PDF). The Pharma 1000. November 2021. Retrieved 29 December 2022.
tufts.edu (Global: 155th place; English: 138th place)
csdd.tufts.edu
- Tufts Center for the Study of Drug Development (November 18, 2014). "Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion". Tufts University. Archived from the original on 2014-11-21. Retrieved 2015-12-01.
wavedata.co.uk (Global: low place; English: low place)
- "Guessing at prices means losing money" (PDF). Generics Bulletin: 10. 8 Sep 2006. Archived (PDF) from the original on 9 September 2016.
web.archive.org (Global: 1st place; English: 1st place)
- "Food & Drug Administration, Generic Drugs: Questions and Answers". Food and Drug Administration. January 12, 2010. Archived from the original on June 9, 2009. Retrieved 2010-02-03.
- "Biosimilar and Interchangeable Products". U.S. Food and Drug Administration. Archived from the original on November 1, 2017. Retrieved 5 May 2018.
- "Pediatric Research Equity Act of 2007" (PDF). Food and Drug Administration. Archived from the original (PDF) on July 9, 2009.
- Lazarus, David (March 25, 2013). "An insider's view of generic-drug pricing". Los Angeles Times. Archived from the original on August 4, 2019. Retrieved December 26, 2025.
- "FDA White Paper: Generic Drug Prices in the US Are Lower Than Drug Prices in Canada". FDA. 6.US Food and Drug Administration, Office of Planning. Archived from the original on February 20, 2004. Retrieved 21 May 2018.
- Tufts Center for the Study of Drug Development (November 18, 2014). "Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion". Tufts University. Archived from the original on 2014-11-21. Retrieved 2015-12-01.
- "Authorized Generics". Generic Pharmaceutical Association (GPhA). 2008. Archived from the original on 2008-05-29. Retrieved 2008-06-16.
- "Savings From Generic Drugs Purchased at Retail Pharmacies". Food and Drug Administration. April 2004. Archived from the original on 2008-02-23. Retrieved 2008-07-11.
- "The role of reverse engineering in the development of generic formulations". www.clihouston.com. Archived from the original on 18 October 2020. Retrieved 23 May 2017.
- "Guessing at prices means losing money" (PDF). Generics Bulletin: 10. 8 Sep 2006. Archived (PDF) from the original on 9 September 2016.
- "Part 320--Bioavailability and Bioequivalence Requirements". U.S. Food and Drug Administration, Department of Health and Human Services. 1 April 2008. Code of Federal Regulations 320 Title 21, Volume 5 CFR 320 21/5. Archived from the original on 2008-10-08. Retrieved 15 June 2008.
- "The Rules Governing Medicinal Products in the European Union". EudraLex. Archived from the original on 2010-05-28. Retrieved 15 June 2008.
- "European Medicines Agency". Archived from the original on 2009-12-22. Retrieved 15 June 2008.
- "National Institute for Health Sciences, Division of Drugs Guidances". Japan. Archived from the original on 2019-05-15. Retrieved 15 June 2008.
- "Generic Initiative for Value and Efficiency (GIVE)". FDA. October 4, 2007. Archived from the original on October 18, 2007. Retrieved 2008-06-15.
- "Orange Book Annual Preface, Statistical Criteria for Bioequivalence". Approved Drug Products with Therapeutic Equivalence Evaluations 29th Edition. U.S. Food and Drug Administration Center for Drug Evaluation and Research. 2009-06-18. Archived from the original on June 6, 2009. Retrieved 2009-08-10.
- "Approved Drug Products with Therapeutic Equivalence Evaluations, Preface". U.S. Food and Drug Administration. Archived from the original on August 19, 2000. – an explanation of FDA terms and procedures
- "Guidance for Industry: 180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act" (PDF). FDA, Center for Drug Evaluation and Research (CDER). June 1998. Archived from the original (PDF) on July 10, 2009. Retrieved August 24, 2009.
- "Paragraph IV Drug Product Applications: Generic Drug Patent Challenge Notifications". FDA, Office of Generic Drugs (OGD). 2008-06-11. Archived from the original on January 23, 2001. Retrieved 2008-06-16.
- "Bristol-Myers Squibb press release on successful defense of Plavix patent". Archived from the original on 2007-07-04.
- "Bristol-Myers Squibb - Newsroom - News Releases". Archived from the original on 2007-10-16. Retrieved 2018-12-20.
- "Apotex press release on successful challenge of Norvasc patent". Archived from the original on 2018-03-19. Retrieved 2017-12-18.
- "Apotex press release on successful challenge of Paxil patent". Archived from the original on August 7, 2007.
- "#223: Authorized Generic Drug Study". U.S. Federal Trade Administration (FTC). August 2011. Archived from the original on 2017-05-16. Retrieved 2016-09-14.
- Carrier MA, Wander D (2012). "Citizen Petitions: An Empirical Study" (PDF). Cardozo Law Review. 34: 249–293. Archived from the original (PDF) on 2016-08-03. Retrieved 2016-09-14.
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, et al. (2005). "Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials". The Annals of Pharmacotherapy. 39 (7–8): 1188–1193. doi:10.1345/aph.1G003. PMID 15914517. S2CID 11685122. Archived from the original on 2011-06-16.
- "Generic medicines training kit: safe and appropriate use of generic medicines". Pharmaceutical Society of Australia Competency Standards for Pharmacists in Australia 2003. National Prescribing Service Limited (NPS). 2003-07-09. Archived from the original on 2009-10-20. Retrieved 2010-01-24."Prescribers may disallow brand switching by ticking the relevant box on the PBS prescription form"
- "FDA Update: Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg". U.S. Food and Drug Administration. 2012-10-03. Archived from the original on October 6, 2012. Retrieved 2013-04-20.
- "564 PLIVA, Inc. v. Mensing" (PDF). Supreme Court of the United States. 2011. Archived from the original (PDF) on 2013-05-12.
- "The Patent Act, 1970". www.ircc.iitb.ac.in. Archived from the original on April 30, 2010.
- "China's Pharmaceutical Industry Lacks Innovation, Lags Behind", China Watch, Washington, D.C., United States: Worldwatch Institute, worldwatch.org, archived from the original on December 26, 2018, retrieved Jan 3, 2012
who.int (Global: 195th place; English: 302nd place)
- "WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO Technical Report Series No. 937): Annex 7 – Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability" (PDF). WHO Technical Report Series No. 937: Annex 7. May 2006. Retrieved 15 June 2008.
wiley.com (Global: 222nd place; English: 297th place)
onlinelibrary.wiley.com
- Caudron, J.‐M.; Ford, N.; Henkens, M.; Macé, C.; Kiddle‐Monroe, R.; Pinel, J. (August 2008). "Substandard medicines in resource‐poor settings: a problem that can no longer be ignored". Tropical Medicine & International Health. 13 (8): 1062–1072. doi:10.1111/j.1365-3156.2008.02106.x. ISSN 1360-2276.
worldcat.org (Global: 5th place; English: 5th place)
search.worldcat.org
- Caudron, J.‐M.; Ford, N.; Henkens, M.; Macé, C.; Kiddle‐Monroe, R.; Pinel, J. (August 2008). "Substandard medicines in resource‐poor settings: a problem that can no longer be ignored". Tropical Medicine & International Health. 13 (8): 1062–1072. doi:10.1111/j.1365-3156.2008.02106.x. ISSN 1360-2276.
- Weinstein, Zohar B.; Zaman, Muhammad H. (21 December 2018). "Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01243-18. ISSN 0066-4804. PMC 6325213. PMID 30397062.
worldwatch.org (Global: low place; English: low place)
- "China's Pharmaceutical Industry Lacks Innovation, Lags Behind", China Watch, Washington, D.C., United States: Worldwatch Institute, worldwatch.org, archived from the original on December 26, 2018, retrieved Jan 3, 2012
zenodo.org (Global: 621st place; English: 380th place)
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH (2009). "Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration". Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.
- Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. (October 2009). "Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration". The Annals of Pharmacotherapy (Submitted manuscript). 43 (10): 1583–1597. doi:10.1345/aph.1m141. PMID 19776300. S2CID 28362065.